Ieq Capital LLC Has $2.02 Million Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Ieq Capital LLC trimmed its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 20.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 103,958 shares of the company’s stock after selling 27,283 shares during the quarter. Ieq Capital LLC’s holdings in 10x Genomics were worth $2,022,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its position in shares of 10x Genomics by 113.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock worth $26,000 after buying an additional 371 shares during the last quarter. Covestor Ltd grew its holdings in 10x Genomics by 501.7% during the first quarter. Covestor Ltd now owns 1,047 shares of the company’s stock valued at $39,000 after purchasing an additional 873 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of 10x Genomics in the first quarter worth $71,000. First Horizon Advisors Inc. boosted its holdings in shares of 10x Genomics by 74.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock worth $37,000 after buying an additional 808 shares during the period. Finally, VitalStone Financial LLC grew its stake in 10x Genomics by 59,900.0% in the 4th quarter. VitalStone Financial LLC now owns 3,600 shares of the company’s stock valued at $201,000 after buying an additional 3,594 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on TXG shares. Leerink Partners initiated coverage on shares of 10x Genomics in a research report on Tuesday, September 3rd. They set an “outperform” rating and a $35.00 target price for the company. Stifel Nicolaus lowered their target price on 10x Genomics from $53.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, July 16th. Leerink Partnrs upgraded 10x Genomics to a “strong-buy” rating in a report on Tuesday, September 3rd. UBS Group lowered their price objective on shares of 10x Genomics from $30.00 to $25.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 13th. Finally, Guggenheim reaffirmed a “neutral” rating on shares of 10x Genomics in a research report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, 10x Genomics presently has an average rating of “Moderate Buy” and an average price target of $31.60.

Insider Buying and Selling at 10x Genomics

In other news, CEO Serge Saxonov sold 6,749 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $152,054.97. Following the sale, the chief executive officer now owns 882,467 shares in the company, valued at $19,881,981.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Serge Saxonov sold 6,749 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $152,054.97. Following the sale, the chief executive officer now directly owns 882,467 shares of the company’s stock, valued at $19,881,981.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Justin J. Mcanear sold 2,961 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $66,711.33. Following the completion of the sale, the chief financial officer now directly owns 143,242 shares of the company’s stock, valued at approximately $3,227,242.26. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,061 shares of company stock worth $316,794. 10.03% of the stock is currently owned by insiders.

10x Genomics Stock Down 3.4 %

Shares of 10x Genomics stock opened at $22.68 on Monday. 10x Genomics, Inc. has a 12-month low of $15.28 and a 12-month high of $57.90. The stock has a market capitalization of $2.70 billion, a P/E ratio of -10.17 and a beta of 1.85. The company has a 50-day simple moving average of $21.01 and a 200 day simple moving average of $25.22.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.15. The company had revenue of $153.10 million during the quarter, compared to analyst estimates of $150.90 million. 10x Genomics had a negative net margin of 37.90% and a negative return on equity of 28.23%. On average, equities analysts anticipate that 10x Genomics, Inc. will post -1.32 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.